Zydus Lifesciences

The reference product, Ascor Injection, recorded about $11.6 million of US sales in the twelve months to June 2026 on IQVIA data, so the direct revenue is modest. The CGT designation carries the value: the exclusivity period runs from first commercial marketing and holds off a second generic for six months. Manufacturing sits at the group's injectables plant at Jarod near Vadodara.

Zydus takes a 50 percent stake for up to 5 million dollars and the Horana plant will make drugs for Sri Lanka's retail market, giving it a local base in a neighbour looking to cut import dependence.

The deal hands Zydus an established US specialty oncology platform anchored by ROLVEDON, used to prevent febrile neutropenia in cancer patients. About 66 percent of Assertio shares were tendered before the merger closed.